Top 10 Warren Buffett Stocks To Own For 2019

Hey, Alexa, can anything stop Amazon?

Shares of the e-commerce king, which is also now a cloud computing giant, connected-home leader, drone company, freight airline, Hollywood studio and even a traditional brick-and-mortar retailer, rose above $900 for the first time Tuesday.

It’s another all-time high.

Amazon (AMZN, Tech30) stock is on a seven-day winning streak. The shares have gained 7% during that stretch and more than 20% this year.

As a result, Amazon is worth more than $430 billion. That’s nearly twice the market value of its rival Walmart (WMT), which has a market cap of a mere $220 billion.

Only Apple (AAPL, Tech30), Google owner Alphabet (GOOGL, Tech30) and Microsoft (MSFT, Tech30) are worth more than Amazon. The Jeff Bezos-led company is now more valuable than Facebook (FB, Tech30) and Warren Buffett’s Berkshire Hathaway (BRKB).

And with that $900 stock price, Amazon is approaching some rarefied air.

Top 10 Warren Buffett Stocks To Own For 2019: Catabasis Pharmaceuticals, Inc.(CATB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) got a boost, shooting up 46 percent to $6.52. Catabasis Pharmaceuticals and Sarepta Therapeutics Inc (NASDAQ: SRPT) reported a joint research collaboration in Duchenne Muscular Dystrophy.

Top 10 Warren Buffett Stocks To Own For 2019: EPAM Systems, Inc.(EPAM)

Advisors’ Opinion:

  • [By Anders Bylund, Chuck Saletta, and Brian Feroldi]

    Read on to see why they pickedAllstate(NYSE:ALL),EPAM Systems(NYSE:EPAM), andUniversal Display(NASDAQ:OLED).

    Image source: Getty Images.

Top 10 Warren Buffett Stocks To Own For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

Top 10 Warren Buffett Stocks To Own For 2019: Sack Lunch Productions (SAKL)

Advisors’ Opinion:

  • [By James E. Brumley]

    Tuesday morning, Sack Lunch Productions Inc (OTCMKTS:SAKL) posted its results for the third quarter (ending September 30th) of the year. They were as strong as you might suspect, with the top line rolling in at $5.35 million, and $142,983 of that turning into net income. That top and bottom line were actually down a bit from the year-ago comparables, though investors should bear in mind that the third quarter of last year was an unusually tough comparison of $6.02 million in sales, and income of $688,845. That was a true breakout quarter for the company’s signature event – Slide the City – and many participants may have come simply to see what it was. The follow-up year (this year), SAKL may not have had the same curiosity factor compelling people to attend.

    Sack Lunch Productions, for the unfamiliar, it’s the name behind event-oriented businesses called Slide the City, Lantern Fest, The Dirty Dash, the Color Me Rad 5K run, and most recently, the Trike Riot. Those are a 1000-foot Slip-n-Slide, a flying lantern release, a mud run, a color-splashing fun run, and a tricycle riding course for kids of all ages and sizes. The events aren’t just fun – they’re FUN!

    They’re also surprisingly profitable. While attendance and per-participant revenue varies, with the average revenue of $30 per participant being at the low end of the scale ( as is the average event attendance of 2500), gross revenue of $75,000 per event is a low-end expectation…

    … not that SAKL hasn’t done some more number crunching of its own. This year, it expects to host roughly 250 events and drive $17 million worth of revenue per event, up about 80% from 2015’s top line. Some of those are being put on by Sack Lunch Productions itself, while others are being hosted by franchisees. Whatever the case, that works out to average revenue of $72,000 per event, with the franchised ones being low-cost to no-cost events for SAKL.

    Regardless, the trend is an impressive one, all

Top 10 Warren Buffett Stocks To Own For 2019: Odyssey Marine Exploration Inc.(OMEX)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at this week’s penny stock gainers, we’ll give you that leg up with one of our top-rated penny stocks from our proprietary stock ranking system…

    Penny Stock Current Share Price (March 26) Last Week’s Gain
    Cartesian Inc. (OTCMKTS: CRTN) $0.39 170.69%
    Odyssey Marine Exploration Inc. (Nasdaq: OMEX) $8.76 135.90%
    iFresh Inc. (Nasdaq: IFMK) $8.25 64.64%
    China Auto Logistics Inc. (Nasdaq: CALI) $4.68 47.43%
    National American University Holdings Inc. (Nasdaq: NAUH) $1.20 39.29%
    Document Security Systems Inc. (NYSE: DSS) $1.58 33.91%
    Blonder Tongue Labs Inc. (NYSE: BDR) $0.77 33.90%
    CareDx Inc. (Nasdaq: CDNA) $7.49 29.88%
    Mediwound Ltd. (Nasdaq: MDWD) $5.10 26.51%
    New York & Co. Inc. (NYSE: NWY) $3.37 26.35%

    Don’t Miss This Shot at a $78,000 Windfall: This tiny firm is about to make the entire world wire-free. As its game-changing technology revolutionizes the global power structure, its stock could hand investors a massive return. Learn more…

Top 10 Warren Buffett Stocks To Own For 2019: Ethan Allen Interiors Inc.(ETH)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Ethan Allen Interiors (ETH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Dan Caplinger]

    Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump weighed on the healthcare sector, and some individual stocks took particularly hard hits. Among the worst performers were Perrigo (NYSE:PRGO), Novadaq Technologies (NASDAQ:NVDQ), and Ethan Allen Interiors (NYSE:ETH). Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Warren Buffett Stocks To Own For 2019: PHI, Inc.(PHIIK)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap offshore oil and gas services stock PHI Inc (NASDAQ: PHIIK):

    We’re a little bit late to the party here, but that’s ok – there’s still some meat left on the bone, so to speak. Were looking for the stock to continue on to the lower edge of a long-term (and bearish) trading range that should allow it to peel back to at least the lower $12’s. We’ve see PHIIK shares tumble with great speed and distance a couple of times already, and we’re about halfway through round three.

Top 10 Warren Buffett Stocks To Own For 2019: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    The simplest way is to use bullish call strategies on the S&P 500 Information Technology Sector SPDR exchange-traded fund (NYSE Arca: XLK).

    You can use any of his strategies, from buying call options to bull call spreads or the “loophole trade,” as he calls it, which cuts down on risk.

  • [By Jim Crumly]

    Technology was the strongest sector, withTechnology Select Sector SPDR ETF (NYSEMKT:XLK) up 1.3%.Consumer stocks were the biggest laggards; theConsumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) lost 0.9%.

  • [By Craig Jones]

    Kevin Kelly, the managing partner at Kelly & Co., spoke on Bloomberg Markets about a bullish options trade in Technology Select Sector SPDR Fund (NYSE: XLK).

  • [By ]

    What My System Flagged As A Buy This Week
    It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

Top 10 Warren Buffett Stocks To Own For 2019: Carter's, Inc.(CRI)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After running through their scenarios,Boruchow comes up with five losers from Trump’s tax plans: Carters (CRI), Urban Outfitters (URBN), Under Armour (UA), Fossil Group (FOSL) and Gap (GPS). He explains why:

  • [By Steve Symington]

    Carter’s Inc.(NYSE:CRI)announced first-quarter 2018 results on Thursday morning, detailing a strong performance in spite of the negative impact of the recent bankruptcy of Toy “R” Us on its large wholesale segment. Though shares initially fell almost 5% early on, Carter’s stock recovered to trade modestly higher by this afternoon.

Top 10 Warren Buffett Stocks To Own For 2019: Aimia Inc. (GAPFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Aimia (OTCPK:GAPFF) (TSX: AIM, AIM.PR.A, AIM.PR.B, AIM.PR.C)

    As some background, we are intimately familiar with Aeroplan and Air Canada (OTCQX:ACDVF) not just as investors but as extraordinarily heavy consumers. As both an Air Canada top tier elite and Aeroplan top tier member I generate well in excess of 1.5 million Aeroplan miles annually, half from flying Air Canada and its partners and the other half from spending. As consumers we were concerned with Air Canada’s decision (though we expect more details to come out that will alleviate these concerns) but as investors we understand that the fundamental business model of mileage programs are incredibly attractive and that Aimia presents an incredibly rare and lucrative investment opportunity for the investor discerning enough to dig into the company.